Next Article in Journal
Inhaled Argon Impedes Hepatic Regeneration after Ischemia/Reperfusion Injury in Rats
Next Article in Special Issue
Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia
Previous Article in Journal
Expanding Role of Dopaminergic Inhibition in Hypercapnic Responses of Cultured Rat Carotid Body Cells: Involvement of Type II Glial Cells
Open AccessReview

Immune-Checkpoint Blockade Therapy in Lymphoma

1
Department of Hematology, National Cancer Center Hospital East, Kashiwa 277–8577, Japan
2
Department of Hematology, Kameda Medical Center, Kamogawa 296–8602, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(15), 5456; https://doi.org/10.3390/ijms21155456
Received: 11 June 2020 / Revised: 27 July 2020 / Accepted: 28 July 2020 / Published: 30 July 2020
(This article belongs to the Special Issue Novel Approaches to Hematologic Malignancies by Immunotherapy)
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective. View Full-Text
Keywords: hematologic malignancies; immunotherapy; programmed cell-death protein 1 (PD-1) hematologic malignancies; immunotherapy; programmed cell-death protein 1 (PD-1)
MDPI and ACS Style

Kuzume, A.; Chi, S.; Yamauchi, N.; Minami, Y. Immune-Checkpoint Blockade Therapy in Lymphoma. Int. J. Mol. Sci. 2020, 21, 5456.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop